CONTACT US: Contact info
|
Citation |
Collins LK, Pande LJ, Chung DY, Nichols SD, McCall KL, Piper BJ. Prev. Med. 2019; 123: 95-100. |
|
Affiliation |
Department of Medical Education, Geisinger Commonwealth School of Medicine, USA; Center for Pharmacy Innovation and Outcomes, Geisinger Precision Health Center, USA. Electronic address: bpiper@som.geisinger.edu. |
|
Copyright |
(Copyright © 2019, Elsevier Publishing) |
|
DOI |
|
PMID |
30763629 |
|
Abstract |
Fentanyl is an important opioid for pain management, but also has exceptional potential for misuse. Seven states have implemented opioid prescribing laws. The objectives of this study were to: 1) characterize the temporal pattern of fentanyl, fentanyl analogue, and other opioid use over the past decade, and 2) determine whether opioid prescribing laws impacted fentanyl use in the US. Drug weights were obtained from the US Automated Reports of Consolidated Orders System (June 2018), a comprehensive publically available resource, from 2006 to 2017 for fentanyl, sufentanil, remifentanil, alfentanil, other prescription opioids, and analyzed by presence of a state opioid prescribing law. Fentanyl, corrected for population, was reduced from 2016 to 2017 (-17.9%) and these decreases significantly exceeded the changes in hydrocodone (-12.3%), oxycodone (-10.1%), morphine (-13.3%), or codeine (-8.8%). Fentanyl showed a particularly large decline in Maine, a state with a strong opioid prescribing law. There was a 3.5 fold difference in fentanyl (μg per capita) in Alaska (488.2) relative to Oregon (1718.4). Hospital use of remifentanil and sufentanil tripled from 2006 to 2017. Although all states experienced a 2016 to 2017 decline in fentanyl, and this reduction was larger than many other prescription opioids, the rate of decline varied over three-fold between states. Strong state laws may account for a portion of the variance in fentanyl and other opioid reductions. The population health risks of fentanyl and fentanyl analogues warrants ongoing vigilance. Language: en |
|
Keywords |
Alfentanil; Epidemiology; Opioid; Remifentanil; Sufentanil |